Reprogramming lymphoblastoid cell lines into induced pluripotent stem cells for disease modeling

Abstract Lymphoblastoid cell lines (LCLs) are human B lymphocytes immortalized by Epstein-Barr virus (EBV). Compared with peripheral blood mononuclear cells and dermal fibroblasts, the conventional starting materials for iPSC derivation, LCLs can be expanded indefinitely from an archived vial, require no further sampling, and are already linked to decades of genotype and clinical annotation in public biobanks. Since the first proof of concept in 2011, reprogramming of LCLs into induced pluripotent stem cells (iPSCs) has evolved into a high-throughput platform, yet the methodological diversification of the past decade, the structure of the global LCL biobank network, and the extent to which LCL-derived iPSCs (LCL-iPSCs) have actually been used in cardiovascular research have not been reviewed together. This article reviews fifteen years of progress, tracing the evolution from episomal vector protocols, through p53 inhibition and standardized workflows, to electroporation, microfluidics, and multiplexing. We describe the global network of LCL biobanks, including Coriell, CEPH, NLGIP, RIKEN, and the Chinese National Immortalized Cell Bank covering 49 ethnic groups, and its value in overcoming the ancestral underrepresentation of current iPSC collections. We then synthesize disease modeling applications with a focus on cardiac disease, distinguishing throughout between findings demonstrated directly with LCL-iPSCs, findings obtained with iPSCs from other starting materials, and applications that remain prospective. We analyze current bottlenecks, namely reprogramming efficiency, genetic instability, and quality-control standardization, and discuss future directions, including massively parallel reprogramming, multi-ancestry iPSC biobanking, cardiac organoids, and gene editing-based variant assessment.

Authors

Institutions

Publication Details

Journal
Discover Medicine
Published
2026-11-15
DOI
https://doi.org/10.1007/s44337-026-00745-y
Primary Topic
Pluripotent Stem Cells Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Reprogramming lymphoblastoid cell lines into induced pluripotent stem cells for disease modeling

Hao Sun, Fanfan Gao, Yun Sun
Discover Medicine
Pluripotent Stem Cells Research
article

Reprogramming lymphoblastoid cell lines into induced pluripotent stem cells for disease modeling

Hao Sun, Fanfan Gao, Yun Sun
article en

Abstract

Abstract Lymphoblastoid cell lines (LCLs) are human B lymphocytes immortalized by Epstein-Barr virus (EBV). Compared with peripheral blood mononuclear cells and dermal fibroblasts, the conventional starting materials for iPSC derivation, LCLs can be expanded indefinitely from an archived vial, require no further sampling, and are already linked to decades of genotype and clinical annotation in public biobanks. Since the first proof of concept in 2011, reprogramming of LCLs into induced pluripotent stem cells (iPSCs) has evolved into a high-throughput platform, yet the methodological diversification of the past decade, the structure of the global LCL biobank network, and the extent to which LCL-derived iPSCs (LCL-iPSCs) have actually been used in cardiovascular research have not been reviewed together. This article reviews fifteen years of progress, tracing the evolution from episomal vector protocols, through p53 inhibition and standardized workflows, to electroporation, microfluidics, and multiplexing. We describe the global network of LCL biobanks, including Coriell, CEPH, NLGIP, RIKEN, and the Chinese National Immortalized Cell Bank covering 49 ethnic groups, and its value in overcoming the ancestral underrepresentation of current iPSC collections. We then synthesize disease modeling applications with a focus on cardiac disease, distinguishing throughout between findings demonstrated directly with LCL-iPSCs, findings obtained with iPSCs from other starting materials, and applications that remain prospective. We analyze current bottlenecks, namely reprogramming efficiency, genetic instability, and quality-control standardization, and discuss future directions, including massively parallel reprogramming, multi-ancestry iPSC biobanking, cardiac organoids, and gene editing-based variant assessment.

Discover MedicineVol. 3(1)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Yunnan University of Traditional Chinese Medicine (CN)
Pluripotent Stem Cells Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Reprogramming lymphoblastoid cell lines into induced pluripotent stem cells for disease modeling — Hao Sun, Fanfan Gao, et al. · Discover Medicine (2026) | TGRS Research Map | TGRS